Comparative Pharmacology
Head-to-head clinical analysis: AZO GANTRISIN versus SULSOXIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AZO GANTRISIN versus SULSOXIN.
AZO GANTRISIN vs SULSOXIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulfamethoxazole is a competitive inhibitor of dihydropteroate synthase, blocking bacterial folic acid synthesis. Phenazopyridine is an azo dye with local analgesic effects on urinary tract mucosa.
Bactericidal; inhibits cell wall synthesis by binding to penicillin-binding proteins (PBPs) and disrupting peptidoglycan cross-linking.
AZO GANTRISIN (phenazopyridine 100 mg / sulfisoxazole 500 mg): 2 tablets orally 4 times daily for 2 days, then 1 tablet 4 times daily for up to 5 days.
500 mg orally 4 times daily for 10-14 days (or 1 g orally 4 times daily for severe infections).
None Documented
None Documented
Sulfamethoxazole: 9-12 hours (adults with normal renal function), prolonged to 20-50 hours in renal impairment; trimethoprim component: 8-11 hours. Clinical context: dosing interval adjusted based on CrCl.
8 hours (terminal) — extends in renal impairment (up to 24 hours in CrCl <30 mL/min); requires dose adjustment
Renal: 70-100% (sulfamethoxazole and metabolites; 15-30% as unchanged drug; remainder as acetylated and glucuronide conjugates). Biliary/fecal: <3%.
Renal: 70% (unchanged); biliary/fecal: 20%; minor hepatic metabolism (<10%)
Category C
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic